Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer

Published:2020-09 Issue:1 Volume:108 Page:212-224
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Yin Limei,Xue Jianxin,Li Rui,Zhou Lin,Deng Lei,Chen Lin,Zhang Yan,Li Yanying,Zhang Xuanwei,Xiu Weigang,Tong Ruizhan,Gong Youling,Huang Meijuan,Xu Yong,Zhu Jiang,Yu Min,Li Mengqian,Lan Jie,Wang Jin,Mo Xianming,Wei Yuquan,Niedermann Gabriele,Lu You

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference31 articles.

1. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy;Sharabi;Lancet Oncol,2015

2. Radiotherapy combination opportunities leveraging immunity for the next oncology practice;Herrera;Cancer J Clin,2017

3. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated;Demaria;Int J Radiat Oncol Biol Phys,2004

4. Optimizing dose per fraction: A new chapter in the story of the abscopal effect?;Formenti;Int J Radiat Oncol Biol Phys,2017

5. DNA exonuclease trex1 regulates radiotherapy-induced tumour immunogenicity;Vanpouille-Box;Nat Commun,2017

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors;Radiotherapy and Oncology;2024-10

2. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

3. Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients;Cancer Medicine;2024-09

4. Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study;Radiotherapy and Oncology;2024-07

5. A real-world analysis of stereotactic body radiotherapy combined with immunotherapy in advanced or recurrent non-small cell lung cancer (NSCLC): A single-center experience;Clinical and Translational Radiation Oncology;2024-07